Abstract: Acylated imidazolyl-O,N-acetals of the formula ##STR1## and their pharmaceutically acceptable salts and metal complexes wherein R is alkyl, alkenyl, alkinyl, cycloalkyl, halogenoalkyl, optionally substituted phenyl, optionally substituted phenoxyalkyl, alkylamino, dialkylamino or optionally substituted phenylamino;X is halogen, alkyl, cycloalkyl, alkoxy, halogenoalkyl, alkylthio, alkoxycarbonyl, optionally substituted phenyl, optionally substituted phenoxy, optionally substituted phenylalkyl, amino, cyano or nitro; andN is 0 or an integer of from 1 to 5;Are useful as antimicrobial agents, particularly for their use in treating mycotic infections in humans and animals.

Abstract: Antimycotic compositions in topical or vaginal administration form are prepared wherein the active agent is imidazol-1-yl-(4-phenoxyphenyl)-(pyridin-2-yl)phenylmethane in combination with a pharmaceutically acceptable carrier suitable for topical application to the skin of a human or suitable for vaginal administration to humans. Such compositions are useful for treating mycoses in humans.

Abstract: Azol-1-ylmethanes substituted on the methane carbon atom by (a) phenyl or lower alkyl and (b) by a biphenyl-4-yl, 4-phenoxyphenyl, 4-phenylthiophenyl, 4-phenylsulfinylphenyl or 4-phenylsulfonylphenyl group are antimycotic and antibacterial agents. The compounds, of which (biphenyl-4-yl)phenyl-imidazol-1-ylmethane is a typical example, are prepared from the correspondingly substituted carbinol through treatment with thionyl-bis-azole or from the correspondingly substituted methyl halide with the azole or a derivative thereof.

Abstract: Imidazoles of the formula ##STR1## and pharmaceutically acceptable nontoxic salts thereof, wherein X is methyl or chloro,Y is methyl or chloro, or, when Z is methyl or chloro, Y is hydrogen, andZ is methyl or chloro, or, when Y is methyl or chloro, Z is hydrogen,Are useful as antimycotics for the treatment of mycotic infections in humans and animals. The imidazoles may be produced by reacting the corresponding triphenylmethylcarbinol with a brominating or chlorinating agent and thereafter reacting the resultant triphenylmethyl halide, either with or without isolation, with imidazole in the presence or absence of an acid-binding agent, or they may be prepared by reacting a triphenylmethyl halide with imidazole, either in the presence or absence of an acid-binding agent.

Abstract: The invention relates to imidazolylcarboxylic acid amide antimycotic compositions and their use.

Abstract: Pharmaceutical compositions are produced which comprise an antimycotically effective amount of a compound of the formula ##STR1## or a pharmaceutically acceptable non-toxic salt thereof wherein R.sup.1 is an unsubstituted or substituted aryl moiety,R.sup.2 is hydrogen, alkyl, alkenyl, cycloalkyl, unsubstituted or substituted aryl or unsubstituted or substituted aralkyl, andR.sup.3 is hydrogen, alkyl or cycloalkyl,Provided that when R.sup.3 is hydrogen, R.sup.2 cannot be hydrogen, in combination with a pharmaceutically acceptable non-toxic inert diluent or carrier.

Abstract: N-methyl-imidazole derivatives of the formula: ##STR1## or a pharmaceutically acceptable non-toxic salt thereof, wherein X is an unsubstituted or substituted 6-membered heteroaromatic moiety having two nitro heteroatoms,Y is an unsubstituted or substituted aliphatic moiety, an unsubstituted or substituted cycloaliphatic moiety, an unsubstituted or substituted aralkyl moiety or an unsubstituted or substituted aryl moiety, andZ is an unsubstituted or substituted aliphatic moiety, an unsubstituted or substituted cycloaliphatic moiety, an unsubstituted or substituted aralkyl moiety, an unsubstituted or substituted aryl moiety, an unsubstituted or substituted pyridyl moiety or an alkoxycarbonyl moiety,Are useful as antimycotic agents.

Abstract: Antimycotic compositions are produced which comprise an antimycotically effective amount of a 1,2,4-triazole of the formula: ##STR1## or a pharmaceutically acceptable non-toxic salt thereof wherein X.sup.1 is hydrogen or alkyl;X.sup.2 is hydrogen or alkyl;R.sup.1 is alkyl, unsubstituted or substituted aryl or unsubstituted or substituted aralkyl;R.sup.2 is hydrogen, alkyl or unsubstituted or substituted aryl;R.sup.3 is alkyl, cycloalkyl, unsubstituted or substituted aryl or unsubstituted or substituted aralkyl; andY is a keto group or a functional derivative of a keto group, in combination with a pharmaceutically acceptable non-toxic, inert diluent or carrier.

Abstract: Imidazoles of the formula ##STR1## and pharmaceutically acceptable nontoxic salts thereof, wherein X is methyl or chloro,Y is methyl or chloro, or, when Z is methyl or chloro, Y is hydrogen, andZ is methyl or chloro, or, when Y is methyl or chloro, Z is hydrogen,Are useful as antimycotics for the treatment of mycotic infections in humans and animals. The imidazoles may be produced by reacting the corresponding triphenylmethylcarbinol with a brominating or chlorinating agent and thereafter reacting the resultant triphenylmethyl halide, either with or without isolation, with imidazole in the presence or absence of an acid-binding agent, or they may be prepared by reacting a triphenylmethyl halide with imidazole, either in the presence or absence of an acid-binding agent.

Abstract: Antimycotic compositions are produced which comprise an antimycotically effective amount of a 1,2,4-triazole of the formula: ##STR1## or a pharmaceutically acceptable non-toxic salt thereof wherein X.sup.1 is hydrogen or alkyl;X.sup.2 is hydrogen or alkyl;R.sup.1 is alkyl, unsubstituted or substituted aryl or unsubstituted or substituted aralkyl;R.sup.2 is hydrogen, alkyl or unsubstituted or substituted aryl;R.sup.3 is alkyl, cycloalkyl, unsubstituted or substituted aryl or unsubstituted or substituted aralkyl; andY is a keto group or a functional derivative of a keto group, in combination with a pharmaceutically acceptable non-toxic, inert diluent or carrier.

Abstract: Antimycotic compositions are produced which comprise an antimycotically effective amount of a 1,2,4-triazole of the formula: ##STR1## or a pharmaceutically acceptable non-toxic salt thereof wherein X.sup.1 is hydrogen or alkyl;X.sup.2 is hydrogen or alkyl;R.sup.1 is alkyl, unsubstituted or substituted aryl or unsubstituted or substituted aralkyl;R.sup.2 is hydrogen, alkyl or unsubstituted or substituted aryl;R.sup.3 is alkyl, cycloalkyl, unsubstituted or substituted aryl or unsubstituted or substituted aralkyl; andY is a keto group or a functional derivative of a keto group, in combination with a pharmaceutically acceptable non-toxic, inert diluent or carrier.

Abstract: Antimycotic compositions are produced which comprise an antimycotically effective amount of a 1,2,4-triazole of the formula: ##STR1## or a pharmaceutically acceptable non-toxic salt thereof wherein X.sup.1 is hydrogen or alkyl;X.sup.2 is hydrogen or alkyl;R.sup.1 is alkyl, unsubstituted or substituted aryl or unsubstituted or substituted aralkyl;R.sup.2 is hydrogen, alkyl or unsubstituted or substituted aryl;R.sup.3 is alkyl, cycloalkyl, unsubstituted or substituted aryl or unsubstituted or substituted aralkyl; andY is a keto group or a functional derivative of a keto group, in combination with a pharmaceutically acceptable non-toxic, inert diluent or carrier.

Abstract: Antimycotic compositions are produced which comprise an antimycotically effective amount of a 1,2,4-triazole of the formula: ##STR1## or a pharmaceutically acceptable non-toxic salt thereof wherein X.sup.1 is hydrogen or alkyl;X.sup.2 is hydrogen or alkyl;R.sup.1 is alkyl, unsubstituted or substituted aryl or unsubstituted or substituted aralkyl;R.sup.2 is hydrogen, alkyl or unsubstituted or substituted aryl;R.sup.3 is alkyl, cycloalkyl, unsubstituted or substituted aryl or unsubstituted or substituted aralkyl; andY is a keto group or a functional derivative of a keto group, in combination with a pharmaceutically acceptable non-toxic, inert diluent or carrier.

Abstract: Imidazolylacetic acid amides of the formula: ##STR1## or pharmaceutically acceptable nontoxic salts thereof WHEREIN EITHERR.sup.1 is phenyl or cycloalkyl, unsubstituted or substituted by one or more substituents; andR.sup.2 is hydrogen;OrR.sup.1 or R.sup.2, together with the nitrogen atom to which they are attached, form a saturated 5 to 7-membered heterocyclic ring which ring may contain an --SO.sub.2 -- or --NY-- moiety wherein Y is alkoxycarbonyl, dialkylaminocarbonyl, or phenyl or diphenylmethyl, unsubstituted or substituted by one or more substituents and wherein said 5 to 7-membered heterocyclic ring itself is otherwise unsubstituted or substituted by one or more substituents; andX.sup.1, x.sup.2, and X.sup.3 and X.sup.4 are the same or different and are each hydrogen or halogen,Are produced byA. reacting a halodiphenylacetic acid amide of the formula: ##STR2## wherein R.sup.1, R.sup.2, X.sup.1, X.sup.2, X.sup.3 and X.sup.4 are as above defined, and Hal is halogen, with imidazole; orB.

Abstract: Imidazolylacetic acid amides of the formula: ##STR1## or pharmaceutically acceptable nontoxic salts thereof wherein either R.sup.1 is phenyl or cycloalkyl, unsubstituted or substituted by one or more substituents; andR.sup.2 is hydrogen; orR.sup.1 and R.sup.2, together with the nitrogen atom to which they are attached, form a saturated 5 to 7-membered heterocyclic ring which ring may contain an --SO.sub.2 -- or --NY-- moiety wherein Y is alkoxycarbonyl, dialkylaminocarbonyl, or phenyl or diphenylmethyl, unsubstituted or substituted by one or more substituents and wherein said 5 to 7-membered heterocyclic ring itself is otherwise unsubstituted or substituted by one or more substituents; andX.sup.1, x.sup.2, x.sup.3 and X.sup.4 are the same or different and are each hydrogen or halogen,Are produced byA. reacting a halodiphenylacetic acid amide of the formula: ##STR2## wherein R.sup.1, R.sup.2, X.sup.1, X.sup.2, X.sup.3 and X.sup.4 are as above defined, and Hal is halogen,With imidazole; orB.

Abstract: Pharmaceutical compositions useful for treating mycotic infections in humans and animals are produced which comprise an antimycotically effective amount of an imidazolylacetic acid amide of the formula: ##STR1## or pharmaceutically acceptable nontoxic salts thereof WHEREINEitherR.sup.1 is phenyl or cycloalkyl, unsubstituted or substituted by one or more substituents; andR.sup.2 is hydrogen;OrR.sup.1 and R.sup.2, together with the nitrogen atom to which they are attached, form a saturated 5 to 7-membered heterocyclic ring which ring may contain an --SO.sub.2 -- or --NY-- moiety wherein Y is alkoxycarbonyl, dialkylaminocarbonyl, or phenyl or diphenylmethyl, unsubstituted or substituted by one or more substituents and wherein said 5 to 7-membered heterocyclic ring itself is otherwise unsubstituted or substituted by one or more substituents; andX.sup.1, x.sup.2, x.sup.3 and X.sup.4 are the same or different and are each hydrogen or halogen,Are produced byA.

Abstract: Cyclic amides of .alpha.-phenyl-.alpha.-imidazolyl acetic acid which are further substituted by an alkyl group or phenyl group on the .alpha.-carbon atom are antimycotic agents. A typical embodiment is diphenyl imidazolyl acetic acid piperidide.

Abstract: Antimycotic compositions are produced which comprise an antimycotically effective amount of a 1,2,4-triazole of the formula: ##STR1## or a pharmaceutically acceptable non-toxic salt thereof wherein X.sup.1 is hydrogen or alkyl;X.sup.2 is hydrogen or alkyl;R.sup.1 is alkyl, unsubstituted or substituted aryl or unsubstituted or substituted aralkyl;R.sup.2 is hydrogen, alkyl or unsubstituted or substituted aryl;R.sup.3 is alkyl, cycloalkyl, unsubstituted or substituted aryl or unsubstituted or substituted aralkyl; andY is a keto group of a functional derivative of a keto group, in combination with a pharmaceutically acceptable non-toxic, inert diluent or carrier.

Abstract: 1-(Imidazol-1-yl)-1-[4-(4-chlorophenyl)phenoxy]-3,3-dimethylbutan-2-one possesses antimicrobial activity, in particular antimycotic activity. The compound is prepared through the condensation of imidazole with 1-chloro-1-[4-(4-chlorophenyl)phenoxy]-3,3-dimethylbutan-2-one.

Abstract: Certain imidazoles and their salts having fungistatic properties are provided which have the following basic structure: ##STR1## in which Y is --(CH.sub.2).sub.n --, --CH.dbd.CH--, O or S; A is N or CH; and n is 0, 1 or 2. Typical fungi are trichophyton species, Microsporon species, Candida species and Penicillium species. These compounds are also active against pathogenic protozoa, viruses and bacteria.